Moderna Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Outlook

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $0.2 billion, or $0.38 per share, beating analyst expectations. The company raised its full-year revenue growth outlook to 15%–25% from 10%, improved its GAAP operating expense outlook by about $0.2 billion, and now expects year-end cash of $8.1 billion–$8.3 billion. Moderna cited international COVID-19 vaccine demand and strategic partnerships, and noted FDA approval of its flu vaccine mFLUSIVA and positive Phase 3 results for melanoma candidate intismeran.